Novartis and Gates Foundation Ink Sickle Cell Gene Therapy Pact
Seeking Low-Cost Practical Option For Sub-Saharan Africa
The Swiss major envisions developing an accessible in vivo gene therapy for SCD that could potentially be administered once directly to the patient without the need to modify cells in a lab.
